A meta-analysis supports the use of oral selective estrogen receptor degraders (SERDs) for patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer. The analysis showed a significant improvement in progression-free survival (PFS) with oral SERDs over standard endocrine therapy in patients who had previously received at least 1 line of endocrine therapy. Oral SERDs significantly improved PFS in various patient groups, and were recommended as a preferred choice for patients with ESR1 mutations and as a potential replacement for fulvestrant. However, patients treated with oral SERDs had a higher incidence of grade 3 or higher adverse events. The results were reported in BMC Cancer.
Source link
Oral SERDs Provide PFS Benefit in HR+, HER2- Advanced Breast Cancer
